This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 1998;279:346.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has issued a public health advisory to alert physicians and others that it has received more than 30 postmarketing reports of patients who have developed epidural or spinal hematomas with the concurrent use of low–molecular-weight heparin and spinal or epidural anesthesia or spinal puncture. Because the reports were made voluntarily from a population of unknown size, estimates of frequency cannot be made. The reports received to date have involved patients treated with enoxaparin sodium injection (Lovenox), but the event would be expected to occur when other drugs with similar pharmacological activity are used in the same manner. All manufacturers of these products are being asked to include additional safety information and recommendations in a boxed warning in their labeling.

Many of the reported hematomas caused neurologic injury, including long-term or permanent paralysis. The agency is advising that the risk of this injury is increased by the use of . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?